Canada · Delayed Price · Currency is CAD kneat.com Earnings Call Transcripts
Fiscal Year 2026
-
Strong revenue growth and customer expansion continue, with ARR reaching CAD 74 million and new strategic clients added. AI-driven features enhance the compliance-focused SaaS platform, and profitability is targeted for 2026 as the company consolidates its leadership in digital validation.
-
Stallion Uranium is fully financed and poised to begin aggressive drilling on its 1,700 sq km land package in the Athabasca Basin, targeting high-grade uranium discoveries. The team’s proven track record, recent survey results, and imminent drilling at the Coyote corridor position the company for near-term news and potential value creation.
Fiscal Year 2025
-
Software revenue rose 33% in 2025, with ARR up 24% year-over-year despite FX and deferred expansions. The company targets cash flow breakeven in 2026, expects incremental ARR growth, and continues to invest in AI and enterprise expansion.
-
Q3 2025 saw 33% SaaS revenue growth and 37% ARR growth, with strong customer expansion and high satisfaction scores. Operating leverage is expected to improve margins to 20–30% in the next 18 months, despite macro headwinds and increased competition.
-
A leading digital validation platform for life sciences is experiencing rapid ARR growth, high customer retention, and strong expansion within existing accounts. Product innovation, including AI integration and agile workflows, supports future market expansion, with profitability targeted by 2026.
-
Kneat.com reported rapid revenue growth, strong customer retention, and significant expansion within the life sciences validation market. The platform’s flexibility, high ROI, and global reach drive customer adoption, while ongoing R&D and a robust partner network support future growth.
-
Q2 2025 saw 32% revenue growth and 43% ARR growth, driven by record new customer wins and SaaS expansion. Gross margin improved to 75%, with non-recurring expenses impacting Q2. Outlook remains strong, with break-even targeted for 2026 and continued digitalization momentum.
-
Q1 2025 saw ARR up 51% and total revenue up 37% year-over-year, driven by SaaS growth and customer expansions. Gross profit rose 38%, and the cash position improved to CAD 74.1 million. Strong pipeline, new partnerships, and leadership hires support continued growth.
-
A leading provider of configurable validation software for life sciences, the company boasts high customer satisfaction, strong revenue retention, and rapid ARR growth. Its platform enables digital transformation, driving expansion within and beyond pharma, with a clear path to profitability.
Fiscal Year 2024
-
Q4 and full-year 2024 saw robust revenue and ARR growth, driven by customer expansions and new strategic wins. Gross margin remained strong at 75%, with continued investment in product, partnerships, and team expansion supporting a positive outlook for 2025.
-
Revenue and ARR grew over 50% year-over-year, with gross margin reaching a record 77%. Expansion within existing and new customers, product enhancements, and a strong pipeline support continued growth, while disciplined investment and a recent equity raise provide flexibility for 2025.
-
Q2 2024 saw ARR up 60% year-over-year to CAD 45.4 million, with SaaS revenue up 54% and total revenue up 45%. Gross margin improved to 74%, driven by customer expansions and a growing partner network, while the outlook remains positive with a robust pipeline.
-
A SaaS platform for life sciences validation is driving strong ARR growth and high customer retention through a land and expand model, with most top pharma companies as clients. The business is expanding its partner ecosystem, improving margins, and targeting a $2B+ core market, with further growth potential in adjacent sectors.